☆ 4.7 Meeting Abstract

Response rate to lenalidomide plus rituximab (R-2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Response rate to lenalidomide plus rituximab (R-2) as independent of number of prior lines of therapy: Interim analysis of initial phase of MAGNIFY phase IIIb study of R2 followed by maintenance in relapsed/refractory indolent NHL.

Rate this paper

Find Funding. Review Successful Grants.

Publish scientific posters with Peeref

Export Citation

Share Paper